A MAB BASE SANDWICH ASSAY FOR AMYLIN & PLASMA

基于 MAB 的胰淀素三明治检测

• 批准号: 3638059
• 负责人: JOY E KODA
• 金额: $ 4.99万
• 依托单位: AMYLIN CORPORATION
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-10-15 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3638059
• 关键词: antibody specificity; epitope mapping; immune complex; immunoaffinity chromatography; immunoglobulin isotypes; immunologic techniques; insulin dependent diabetes mellitus; metabolism disorder diagnosis; monoclonal antibody; noninsulin dependent diabetes mellitus; peptide hormone

The goal of the proposed research is to generate diagnostic reagents and/or therapeutic reagents for diabetes through production of monoclonal antibodies to the peptide hormone, amylin. Amylin is a newly discovered peptide hormone that is active in the control of glucose metabolism and the measurement of peptide levels directly in plasma will be key to further understanding and quantitating the role that the hormone plays in the disease processes of Type I and Type II diabetes. Monoclonal antibody reagents will i) assure stable supplies of high affinity antibodies specific to different epitopes on the amylin protein, ii) be used to make isotope or enzyme conjugated antibodies specific for amylin and, iii) be useful for the development of a sandwich assay for amylin. During Phase I, we will characterize the monoclonal antibodies produced for: i) specificity to amylin, ii) apparent affinity constant, iii) epitope mapping using peptide fragments, iv) ability to form a complex with other monoclonal antibodies and/or available polyclonal antisera, v) immunoglobulin subtype. In Phase 11 we will use these reagents to i) develop a sandwich assay for amylin-, it) construct an affinity column to purify and further characterize amylin from human plasma; iii) identify antibodies that block amylin binding to its receptor and use these antibodies to modulate amylin action in vivo: iv) characterize the metabolic products of amylin.

拟议研究的目标是产生诊断试剂和/或